Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07430696
PHASE2

INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY

Sponsor: University of Kelaniya

View on ClinicalTrials.gov

Summary

Ayurvedic medicines are used extensively in Asia both for benign as well as malignant disease. Despite their widespread use there is scant scientific evidence to prove efficacy. There are anecdotal reports of effectiveness. Patients are often referred to ayurvedic physicians when all other options have been exhausted. We, at the university of Kelaniya , are planning a randomised double blind placebo controlled study to investigate the anticancer effects of an anticancer ayurvedic drug Trishul in patients with rectal cancer. Patients after discussion at the multidisciplinary discussion will be randomised into two groups. One group will receive the active drg and the other will receive matching placebo. This will be additional to the standard treatment advised by the multidisciplinary team. Treatment/Placebo will be started 4 weeks preoperatively and continued for 24 weeks postoperatively. Patients will be followed up in a standard manner. Evidence of any adverse effects, disease recurrence either locally or at a distant site will be recorded. Overall survival and disease free survival will be the primary endpoints.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-05-01

Completion Date

2028-05-01

Last Updated

2026-02-24

Healthy Volunteers

No

Interventions

DRUG

Trishul 750 mg bd orally

Patients randomised to receive Trishul will be give 750 mg of the drug orally ywice daily